That's when its first-quarter results will be published.

April 29 (Reuters) - Teva Pharmaceutical Industries beat Wall Street estimates for first-quarter profit on Wednesday, helped ...

Teva exceeded all sustainability-linked bond targets, linking financial performance to expanded patient access to medicines ...

Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million | Teva Pharmaceuticals has struck a deal to ...

Life Sciences' $400 million commitment to Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) in March could be an example.

Teva Pharmaceutical Industries Ltd (TEVA) reports robust growth in key products and strategic acquisitions, despite facing revenue declines in generics.

For an accessible version of this Press Release, please visit Q1 2026 revenues of ~$4.0 billion increased by 2% in U.S.

Teva’s overall performance topped Wall Street estimates for Q1, according to Bloomberg News, which also pointed out that the ...

Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology ...

Institutional sentiment towards Teva Pharmaceutical Industries Limited (NYSE:TEVA) has shifted significantly following Q4 ...

Teva (TEVA) stock jumps as the company exceeds forecasts with Q1 2026 financials. However, it cut its 2026 earnings outlook ...